Defective Devices and False Claims: What the Company Allegedly Knew Before the Implant

A defective medical device False Claims Act case connects what a manufacturer knew about a faulty product to the government claims its sale caused. A quality team sees repeated failures. A surgeon keeps receiving the implant without the information that might change that choice. A hospital bills Medicare for the procedure. The insider who knows why sales continued may hold the part of that story the claim never shows.

Can a Whistleblower Take Legal Action Against a Medical Device Company?

Yes. A whistleblower can bring a False Claims Act case against a manufacturer that knowingly causes false government claims, including claims submitted by hospitals using its devices. The civil cases against Exactech, Aesculap, St. Jude Medical and Guidant show how the company’s decisions can reach the government’s bill.

The Alere INRatio settlement concerned allegations of billing or causing bills for unreliable blood-coagulation monitors.

The commercial chain matters. The surgeon may choose or strongly influence the implant brand. The hospital buys the product and receives payment for the procedure. Under some consignment arrangements, the manufacturer retains ownership of inventory sitting at the hospital until it is used. Implantation can be the moment the manufacturer makes the sale.

Medicare usually pays for an implanted device within the payment for the hospital stay or outpatient procedure. A device charge may appear on a claim even when the implant receives no separate payment. Following the money therefore means connecting the particular product to the procedure and the provider’s claim.

In the knee cases, the government alleged that known premature failures made the devices unreasonable and unnecessary for the surgeries in which they were used. The Medicare coverage law makes reasonable and necessary treatment a condition of payment. The allegation reaches both sides of the transaction: patients received implants the manufacturer allegedly knew would fail too soon, and taxpayers paid for their use.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

When the Defect Appears After the Claim

A hidden manufacturing defect can leave the surgeon unaware of the problem when the hospital submits its claim. That timing was central to a case involving DePuy’s Pinnacle metal-on-metal hip implants.

In the DePuy whistleblowers’ allegations, the company sold implants that departed from the authorized manufacturing specifications while presenting them as the authorized product. The alleged differences included component dimensions and surface roughness.

The complaint described a patient whose implant allegedly failed because of manufacturing defects and whose hospital submitted a Medicaid claim for the implant and surgery. The court explained that the alleged defects would not have appeared during surgery. Doctors could implant what they understood to be the authorized product and seek payment without knowing the unit differed from it.

The case later ended in dismissal as a sanction for repeated violations of court orders protecting confidential information, without a ruling on whether the defect allegations were true.

For an insider, the sequence matters: what was wrong with the unit, when the problem became visible, what the physician understood and what the hospital billed.

What the Company Knew Before Sales Continued

The defect cases turn on decisions made while the devices were still reaching patients. Exactech’s alleged knowledge concerned successive knee components. Aesculap’s concerned the implant’s bond with bone cement and what it told surgeons. The heart-device cases put the older inventory and the withheld warnings in view.

Exactech and Alleged Successive Knee Failures

Exactech agreed to an $8 million settlement in September 2025 over allegations involving knee replacement devices used in Medicare, Medicaid and Veterans Affairs patients. The Justice Department’s announcement describes separate periods for separate components. The settlement amount reflected Exactech’s financial condition.

The government alleged that Exactech knew as early as January 2008 that its finned tibial tray failed prematurely at an unacceptable rate, yet continued marketing and selling it for surgeries through December 31, 2018.

The second allegation concerned polyethylene components in certain Logic and Truliant knee systems. The government alleged that Exactech knew of unacceptable premature failures as early as January 2019 but continued marketing and selling the affected systems for surgeries through February 7, 2022.

For someone in quality or distribution, that separation matters. A complaint about a metal tray and a complaint about a polyethylene component identify different products and different periods of company knowledge. Matching the component to the surgery keeps the evidence attached to what the patient actually received.

Aesculap and Alleged Bone-Cement Adhesion Failures

Aesculap agreed to pay $38.5 million in November 2025 to resolve allegations that it sold VEGA knee implants it knew would fail prematurely and made unlawful payments to a surgeon. The civil settlement announcement connects those sales to Medicare and Medicaid claims.

The alleged defect was specific. Bone cement did not properly adhere to the implant. The government alleged that Aesculap learned of the problem shortly after the product’s U.S. release, yet sold it to physicians and hospitals without disclosing it. Implants could loosen shortly after surgery, leaving patients with pain, instability and difficulty walking and requiring another operation to replace them.

The government also alleged that Aesculap failed to record, track or report adverse events and did not adequately address the problem. These are decisions inside the company that a surgeon choosing an implant would have had little opportunity to see.

The physician-payment allegations concerned an orthopedic surgeon who had experienced problems with the VEGA. Aesculap allegedly provided consulting payments, international travel and entertainment to induce continued use and recommendations. The same surgeon who saw failures was someone the company allegedly paid to keep using the product.

The Aesculap whistleblowers worked outside the manufacturer, as third-party distributors. Their position in the sales channel put them between the manufacturer’s account of the device and the physicians’ experience using it.

St. Jude and Allegedly Withheld Battery Information

St. Jude Medical agreed to a $27 million settlement in July 2021 over allegations that it knowingly sold defective implantable heart devices to facilities treating patients covered by federal healthcare programs. The government’s account traces the problem to lithium clusters that could short the battery and drain its power prematurely.

The government alleged that St. Jude knew of the battery problem by 2013. When it sought Food and Drug Administration approval for a design change in late 2014, the company allegedly told the agency that no serious injury, permanent harm or death had been reported in connection with the problem. According to the government, St. Jude already knew of two reported serious injuries and one death.

The government alleged that St. Jude continued distributing devices made without the new design. According to its account, the company reported 729 premature battery-depletion events to the Food and Drug Administration in August 2016. Its October 2016 advisory became a Class I recall.

The whistleblower’s complaint alleged that the missing information left the physician unaware of the risk:

The government’s payment theory followed the missing information. It contended that disclosure of the known injuries and death would have led to a recall, preventing the continued sales that caused false claims. The recall date was the endpoint of that account. The decisions that mattered began earlier.

Guidant and the Old Stock Still for Sale

Boston Scientific agreed to a $30 million civil settlement in October 2013 over Guidant’s alleged sale of defective heart devices for implantation in Medicare patients. The Justice Department described an electrical defect in Prizm 2 and Renewal devices that could send a shock back into the device itself, shorting it instead of delivering the needed current to the heart.

The government alleged that Guidant corrected the defects but continued selling its remaining stock of older devices. It also alleged that the company concealed the problem and sent doctors a misleading communication about it.

The government’s complaint alleged that Guidant kept its sales representatives uninformed:

That alleged decision left sales representatives promoting a product without the information the manufacturer held. The quality problem had become a sales decision.

In its separate criminal guilty plea, Guidant admitted misleading the Food and Drug Administration and failing to submit a labeling change concerning the defective devices. The civil case addressed the alleged sale of defective units that health care facilities implanted in Medicare patients.

What Evidence Is Needed to Prove Fraud?

The evidence connects the affected device, the company’s knowledge, the information reaching the physician and the government claim. Complaint files and test results explain the product problem. Sales and clinical records show how an affected unit reached a patient. Billing records connect that procedure to the payer.

Complaint Trends, Testing and Corrective Decisions

Complaint dates establish when reports reached the company. Test results, device evaluations and corrective-action records can show what the company learned and how it responded. Aesculap’s alleged failure to track adverse events and Guidant’s alleged decision about informing sales representatives illustrate why both the technical findings and the response matter.

The comparison is between what the company knew internally and what it communicated outside. A physician receiving reassurance about a product may be seeing a very different account from the quality team handling repeated failures.

Product Identity, Inventory and Implantation

The model and component connect the quality concern to the product supplied. Implant and procedure records connect that product to the patient. In the DePuy allegations, the differences involved manufacturing dimensions and surface roughness. In Exactech, the government identified different components over different periods.

In consignment arrangements, shipment, use and billing records describe different moments in the same transaction.

Guidant’s old-stock allegations show why that matters. Correcting future production left a separate decision about units already available for sale. The affected inventory and the instructions reaching the sales channel belong beside the engineering change.

Physician Communications and the Claim

Warnings, product updates, sales messages and reimbursement instructions show what the provider was told. The physician’s decision and the hospital’s claim show what followed. In Aesculap, the alleged payments to a surgeon added another reason to examine why use continued despite failures.

A 2020 review in the Journal of Forensic and Investigative Accounting identifies access to inside information as a strength of whistleblower cases in uncovering complex financial schemes. For a device insider, that information may be the reason a complaint was closed, a shipment continued or a physician received reassurance.

How Is Medicare Fraud Detected?

In device cases, connecting hospital records with the manufacturer’s product and sales records can reveal what a Medicare claim leaves out. Claims generally do not identify the particular implant by its unique device identifier. The implant record can supply the product identity while the claim supplies the procedure, date and payment request.

That is why quality, regulatory, distribution and billing employees can each see something consequential without seeing the entire chain. We work with insiders to connect those views and identify the company decisions behind the government payment.

Recall Timing, Authorization and Replacement Credits

In a defective-device whistleblower case, the earlier complaint history, continued sales and resulting claims explain how the government came to pay. St. Jude’s battery case makes that sequence concrete: the government alleged that information withheld before the recall allowed affected devices to keep reaching patients.

Food and Drug Administration authorization supplies a different comparison: the product the company was allowed to market against the product it supplied. In the DePuy case, the whistleblowers alleged that manufactured units departed from the authorized specifications. CareFusion’s authorization case concerned allegations that uncleared and unapproved devices reached procedures billed to Medicare and Medicaid.

Aesculap’s separate criminal non-prosecution agreement concerned devices distributed without FDA clearance.

St. Jude’s separate replacement-credit case concerned allegations that missing warranty credits inflated government invoices.

When You Know Why Sales Continued

If you work in quality, regulatory affairs or device sales and know what the company withheld before implantation, talk with our whistleblower experts about the failures and the sales that followed. We build the case with you around the affected devices, the company’s decisions and the government payments, and bring in medical device whistleblower lawyers who understand manufacturing defects and reimbursement. We stay beside you through the case, connecting your knowledge of the product to the decisions that put it into patients.